Trial Profile
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary)
- Indications Basal cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMPOWER-BCC 1
- Sponsors Regeneron Pharmaceuticals
- 08 Mar 2024 This trial has been discontinued in Italy, according to the European Clinical Trials Database record.
- 08 Dec 2023 Final results (n=54) of metastatic basal cell cancer after first-line hedgehog pathway inhibitors were published in the Annals of Oncology.
- 05 Oct 2023 This trial has been discontinued in Spain, according to the European Clinical Trials Database record.